Horizon Space Acquisition II Corp. (HSPT) Company Overview

Horizon Space Acquisition II Corp. was a Cayman Islands special purpose acquisition company, or SPAC, not an operating “space” business. Incorporated on March 21, 2023, it raised cash to identify a private target and complete a business combination. HSPT represented ordinary shares on Nasdaq; HSPTU represented units and HSPTR represented rights. The company’s final IPO prospectus makes the central point explicit: HSPT had no product line, customers, recurring revenue, or operating segment comparable with a normal industrial or technology company.

A public shell with one reportable segment

HSPT’s pre-merger activity was evaluating acquisition candidates and executing a transaction. Its 2025 Form 10-K reported one operating and reportable segment. The chief executive officer monitored trust interest, professional fees, and formation costs—an economic model unlike a company selling goods or services.

The securities investors actually held

HSPT remained a listed acquisition vehicle only until closing. Nasdaq suspended HSPT, HSPTR, and HSPTU after June 12, 2026; SL Science Holding Limited began trading as SLBT on June 15.

HSPT had no customer revenue. Public-share proceeds were placed in a trust invested in U.S. Treasury obligations or qualifying money-market funds, earning interest during the search. The sponsor funded costs outside the trust through private units, advances, and notes. Public holders gained redemption protection; sponsor securities could lose value if no merger closed.

Trust account, sponsor capital, and interest income

Why reported net income was not operating profit

For FY2025, HSPT reported $2.890 million of trust interest, $1.081 million of formation and operating costs, and $1.809 million of net income, yet operating cash flow was negative $1.039 million. Trust income accrued to the redemption pool, while legal, accounting, and advisory costs consumed cash outside it. Conventional margins are meaningless because operating revenue was zero.

The latest standalone period was the quarter ended March 31, 2026. Shareholders had approved the SL Bio combination, redemptions had reduced the trust, and HSPT now carried a large unconditional redemption liability. The March 2026 Form 10-Q is therefore more informative than a headline net-loss figure.

Liquidity, redemptions, and liability reclassification

At the vote, 3,502,404 shares were submitted for redemption. Approval made those elections unconditional, moving them from temporary equity to a liability. It was initially measured at $37.231 million, or $10.63 per share, and remeasured to $37.483 million by March 31. Another 178,285 shares remained conditionally redeemable at about $10.70 each.

What the cash-flow statement reveals

HSPT’s value depended on closing a target. On May 9, 2025, it agreed to combine with SL Bio Ltd., a Taiwan-headquartered developer of cell and gene therapy platforms and non-cellular biologics. The target’s official corporate overview describes preclinical Armed-T and Gamma delta T-cell programs, alongside plant- and milk-derived exosome work. That profile introduced clinical, regulatory, commercialization, and financing risks absent from the trust phase.

The economics of the transaction

What HSPT shareholders received

Shareholders approved the transaction on February 12, 2026, by 5,031,013 votes to 1,166,644. The official shareholder-vote Form 8-K shows that approval and redemption were separate: investors could support the deal yet take trust cash.

The combination closed on June 12, 2026. A successor-company Form 6-K announced completion, and Nasdaq’s corporate-action notice confirmed HSPT’s suspension and SLBT trading from June 15. The analytical object then changed from a trust vehicle to an operating biomedical company.

HSPT’s short history repeatedly changed trust protection, sponsor incentives, transaction probability, and dilution. A timeline is more useful than an encyclopedic history.

From formation to listing to merger

1. March 21, 2023
   HSPT was incorporated in the Cayman Islands as a blank-check company. At this point it had no operations, target, or public capital.
2. July 26, 2024
   Founders acquired 1.725 million founder shares for an aggregate $25,000, roughly 1.45 cents per share. This low basis created powerful closing incentives and potential dilution.
3. November 18-21, 2024
   The IPO and full over-allotment sold 6.9 million public units for $69.0 million. The sponsor bought 213,500 private units for $2.135 million, while the underwriter received 241,500 representative shares.
4. May 9, 2025
   HSPT signed the SL Bio business combination agreement. The story shifted from target-search optionality to execution, redemption, financing, and biotechnology diligence.
5. November 2025-February 2026
   A $690,000 trust deposit extended the original deadline to February 18, 2026. Shareholders later authorized monthly extensions, each requiring the lesser of $50,000 or $0.033 per remaining public share.
6. February-March 2026
   Shareholders approved the deal; 3.502 million shares submitted redemptions and 3.219 million were paid $34.221 million on March 17. The shrinking trust made financing quality more important.
7. June 12-15, 2026
   The combination closed, HSPT’s public securities stopped trading, and SL Science Holding Limited began trading as SLBT.

Delay was costly: extensions required funding, expenses accumulated, and shareholders retained redemption rights. More time could improve closing certainty while leaving less cash for the successor.

A SPAC lacks classic moats such as technology, scale, switching costs, or brand. HSPT’s temporary advantages were a Nasdaq listing, funded trust, sponsor network, and negotiated route to public markets. They mattered only if management closed before time and liquidity ran out.

Structural strengths

Limits of the moat

HSPT’s structure was replicable. Targets could choose other SPACs, traditional IPOs, reverse mergers, strategic sales, or private financing. The sponsor may have helped execution, but the filings show no defensible sourcing franchise or repeatable operating capability.

For an MBA-style resource analysis, the trust and listing were valuable and temporarily scarce to the chosen target, but they were neither durable nor unique. Once the merger closed, the successor’s scientific assets, personnel, financing capacity, and regulatory execution—not HSPT’s shell—became the relevant sources of advantage.

HSPT competed for private-company transactions, not product customers. Rival SPACs sought targets; traditional IPOs, strategic buyers, private financing, and reverse mergers offered alternatives. Strong targets could demand better terms, while weaker targets increased post-close risk.

Alternative routes to public or strategic capital

HSPT secured SL Bio, but closing does not prove superior selection. Success now depends on clinical evidence, regulatory progress, durable financing, and eventual commercial cash flow.

SPAC ownership matters because cost, voting power, redemption rights, and liquidation exposure differ. Public investors paid $10.00 per unit and could redeem. Founders acquired 1.725 million shares for $25,000 and waived trust rights on sponsor securities, creating a strong incentive to close even when public holders preferred cash.

Pre-close ownership and incentives

Post-close control shifted to the operating-company founder

The successor’s Schedule 13D shows a decisive governance change: the operating-company founder and affiliates replaced the SPAC sponsor as the controlling bloc. Strategy, financing, board influence, and related-party oversight now require a controlled-company lens.

Pre-close risks centered on execution, redemptions, financing, conflicts, and deadlines. After closing, they migrated into the successor and gained biotechnology uncertainty. The trust protected a pre-close public share; it does not protect SLBT from losses, clinical setbacks, dilution, or repricing.

Risks identified by the filings

What researchers should monitor next

A conventional DCF starts with operating revenue, margins, reinvestment, and free cash flow. HSPT had none of those inputs. Pre-close value was anchored to trust value per share, adjusted for redemption timing, transaction probability, dilution, extension costs, and merger optionality. Trust interest was not recurring operating profit.

The pre-close valuation equation

This is a cash-backed event analysis, not an enterprise DCF. Relevant variables are redemption value, payment timing, and the securities received at closing. Rights add shares, while founder and representative shares dilute public trust capital.

Post-close valuation shifts to SL Science

For the successor, a probability-adjusted biotechnology model is more appropriate. Analysts must estimate clinical and regulatory success, patient population, pricing, manufacturing cost, commercialization expense, intellectual-property durability, and funding dilution. The approximately $5.568 billion implied closing valuation must be tested against evidence, not treated as a cash-flow result.

The key sensitivities are development probability, years to revenue, funding rounds, and the discount rate for an early-stage platform. Future financing can change both cash and share count, so enterprise and equity value must remain distinct.

HSPT assembled a Nasdaq listing, $69.0 million public trust, sponsor capital, and merger mechanics that brought SL Bio to U.S. public markets. The trust was liquid, but unrestricted liquidity was weak: at March 31, 2026, HSPT had $39.391 million in trust assets, $9,586 outside the trust, and a $1.785 million working-capital deficit.

For students, HSPT shows how legal structure shapes incentives. For researchers, it shows why trust interest can make net income economically misleading. For investors, the lesson is to separate trust value from operating value, approval from redemption, and closing from long-term success. The durable story now belongs to the successor.